A Study to Evaluate the Pharmacokinetics and Safety of DBPR108 in Subjects With Renal Impairment

NCT04859439 | Completed Phase 1

• 1 other identifier: HA1118-CSP-009
• Study Type: interventional
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

This is an open-label, single-dose study to evaluate the pharmacokinetics and safety of DBPR108 in subjects with mild, moderate, severe renal impairment and subjects with kidney failure compared to the matched control subjects with normal renal function.

Conditions

Renal Impairment

Outcome Measures

Primary Outcomes (6)

• The pharmacokinetic parameters of DBPR108 in plasma

  Cmax

  Predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, and 48 hours after dosing

• The pharmacokinetic parameters of DBPR108 in plasma

  AUC0-t

  Predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, and 48 hours after dosing

• The pharmacokinetic parameters of DBPR108 in plasma

  AUC0-inf

  Predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, and 48 hours after dosing

• The pharmacokinetic parameters of DBPR108 in urine

  Ae

  predose and 48 hours after dosing

• The pharmacokinetic parameters of DBPR108 in urine

  fe

  predose and 48 hours after dosing

• The pharmacokinetic parameters of DBPR108 in urine

  CLR

  predose and 48 hours after dosing

Secondary Outcomes (6)

• The pharmacokinetic parameters of DBPR108 in plasma

  Predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, and 48 hours after dosing

• The pharmacokinetic parameters of DBPR108 in plasma

  Predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, and 48 hours after dosing

• The pharmacokinetic parameters of DBPR108 in plasma

  Predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, and 48 hours after dosing

• The pharmacokinetic parameters of DBPR108 in plasma

  Predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, and 48 hours after dosing

• The pharmacokinetic parameters of DBPR108 in urine

  predose and 48 hours after dosing

Study Arms (5)

Mild Renal Impairment

EXPERIMENTAL

Subjects will receive a single dose of 100 mg DBPR108

Drug: DBPR108 tablets

Moderate Renal Impairment

EXPERIMENTAL

Subjects will receive a single dose of 100 mg DBPR108

Drug: DBPR108 tablets

Severe Renal function

EXPERIMENTAL

Subjects will receive a single dose of 100 mg DBPR108

Drug: DBPR108 tablets

Kidney failure

EXPERIMENTAL

Subjects will receive a single dose of 100 mg DBPR108

Drug: DBPR108 tablets

Normal Renal function

EXPERIMENTAL

Subjects will receive a single dose of 100 mg DBPR108

Drug: DBPR108 tablets

Interventions

DBPR108 tablets DRUG

Drug: DBPR108, tablet, oral

Also known as: DBPR108

Kidney failure; Mild Renal Impairment; Moderate Renal Impairment; Normal Renal function; Severe Renal function

Eligibility Criteria

• Age: 18 Years - 79 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• All subjects:
• Voluntarily sign the informed consent form, understand the trial procedures, and be willing to comply with all trial procedures and restrictions；
• years to 79 years (inclusive), male and female；
• Male subjects weight ≥50 kg and female subjects weight ≥45 kg. Body mass index (BMI) : 18-30 kg/m2 (inclusive) (BMI= weight (kg)/height2 (m2))；
• Subjects (including partners) are willing to voluntarily use effective contraceptives from screening to at least 6 months after the last dose administration；
• Subjects with RI only:
• Subjects with medically stable RI corresponding to the Classifications of Renal Function based on eGFR: mild RI: 60 to 89 ml/min/1.73m2; moderate RI: 30 to 59 ml/min/1.73m2, severe RI:15-29 ml/min/1.73m2, kidney failure:\<15 ml/min/1.73m2 (not on hemodialysis);
• Not in use of any prescription drug, over-the-counter drug, or herbal medicine within 2 weeks prior to screening, except for the medication necessary for RI/ other comorbidities with no effect on the study drug absorption, distribution, metabolism, or excretion (last more than four weeks in good compliance);
• Based on physical examination, vital sign measurements, 12-lead electrocardiogram (ECG), and clinical laboratory tests (serum potassium: 3.5-5.5 mmol/L);
• Subjects with normal renal function only:
• Weight, age, and sex must be matched with subjects with HI;
• eGFR≥90 ml/min/1.73m2;
• Not in use of any prescription drug, over-the-counter drug, or herbal medicine within 2 weeks prior to screening, except for the medication necessary for underlying conditions other than renal disease with no effect on the study drug absorption, distribution, metabolism, or excretion (last more than four weeks in good compliance).

You may not qualify if:

• All subjects:
• Subjects who have a history of allergic conditions (such as asthma, urticaria), or have a history of allergy to two or more drugs or food, or may be allergic to the test drug and the related compounds;
• Have a history of severe and uncontrolled diseases, such as cardiovascular, respiratory, liver, gastrointestinal, endocrine, hematologic, mental/nervous systems diseases within one year prior to screening；
• Have previously undergone surgery that may affect drug absorption, distribution, metabolism, or excretion (e.g., subtotal gastrectomy), or who have a scheduled surgical plan during the study period;
• Use of any DPP-IV enzyme inhibitor within 2 weeks prior to the screening;
• Drug abuse, or positive urine drug screen at screening；
• Smoking more than 5 cigarettes per day within 3 months prior to screening；
• Average alcohol intake is more than 28g alcohol (male) or 14g (female) per week (14g ≈ 497mL beer, or 44mL spirits with low alcohol content, or 145mL wine) within the 3 months prior to screening, or taking any alcohol within 48 hours before dosing, or a positive ethanol breath test at screening;
• Consumption of grapefruit juice, methylxanthine-rich food or beverage (such as coffee, tea, cola, chocolate, energy drinks) within 48 hours before the administration, or have strenuous exercise, or have other factors affecting drug absorption, distribution, metabolism, excretion, etc.；
• Participation in another clinical trial within 3 months before screening；
• Blood donation (or blood loss) ≥400 mL, or receiving whole blood transfusions or erythrocyte suspension transfusions within 3 months prior to the screening；
• Have acute hepatitis or a chronic liver disease; aspartate aminotransferase (AST), alanine aminotransferase (ALT) or bilirubin \> 2 × upper limit of normal；
• Have a positive result for hepatitis B surface antigen, hepatitis C virus antibody, human immunodeficiency virus antibody, or anti-treponema pallidum specific antibody；
• A pregnant/lactating woman, or has a positive pregnancy test at screening or during the trial；
• Currently receiving, or unable to refrain from expected concomitant cytochrome (CYP) 3A inhibitors and inducers;

Sponsors & Collaborators

• CSPC ZhongQi Pharmaceutical Technology Co., Ltd.: lead

Study Sites (1)

First Affiliated Hospital of Soochow University

Suzhou, China

Location

MeSH Terms

Conditions

Renal Insufficiency

Interventions

DBPR108

Condition Hierarchy (Ancestors)

Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 21, 2021
• First Posted: April 26, 2021
• Study Start: June 15, 2021
• Primary Completion: November 30, 2021
• Study Completion: December 31, 2021
• Last Updated: May 10, 2022

Record last verified: 2022-05

Locations

CN (1)